Svenja Steinbrink

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
In the recent years the prevalent paradigm in drug discovery of " one drug – one target – one disease " , following the assumption that highly selective ligands would avoid unwandted side effects caused by binding to sec-onday non-theratpeutic targets, got reconsidered. The results of post-genomic and network biology showed that proteins rarely act in(More)
  • 1